The Medicines Company has announced completion of patient enrollment in the 13,800-patient global Phase III ACUITY (Acute Catheterization and Urgent Intervention Triage strategY) trial. This randomized trial is evaluating the direct thrombin inhibitor Angiomax (bivalirudin) replacing heparins (unfractionated heparin or enoxaparin) in patients with acute coronary syndromes (ACS). ACUITY is being conducted at 450 trial sites in 17 countries worldwide.
In the U.S. each year, 1.8 million patients are hospitalized for ACS. Ischemic heart disease patients are subject to chest pain that results from a range of conditions, from unstable angina to acute myocardial infarction.